Zacks estimated an EPS of $1.57 for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)

49

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) traded with the volume of 1.22 Million in the previous trading session. The Stock opened its session at $0 and closed at $13.35 by showing decrease of -1.48 percent. Sucampo Pharmaceuticals, Inc. has 1 year price target of $20.25. The stock gained a consensus recommendation of 1.57 on Zacks Investment Research where the scale runs from 1 to 5, 1 representing Strong buy and 5 showing Strong Sell.  The company reported its last quarter on Sep 16.

On Sep 16 Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) reported its EPS in the last quarter as $0.28/Share beating the analyst estimate of $0.27/Share by the difference of $0.01. This showed the surprise of 3.7% in the last quarter earnings. For the Current Quarter, 1 analysts are projecting the mean EPS to be $0.38/share. According to their observations and findings, the stock could provide a high EPS of $0.38/share and a Low EPS of $0.38/share.

The 7 analysts offering 12-month price forecasts for Sucampo Pharmaceuticals Inc have a median target of 19.00, with a high estimate of 29.00 and a low estimate of 14.00. The median estimate represents a +42.32% increase from the last price of 13.35. (CNN MONEY)

Many Analysts provided their foresight on Revenue Estimates of Sucampo Pharmaceuticals, Inc. where they believe that the company has the potential to earn average revenue of $65.95 Million for the current quarter. According to their predictions High & Low revenue estimates are 68.2 Million and 64.5 Million respectively.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) topped its 52-week high price of $17.55 on Nov 30, 2016 and 52-Week Low Price of $9.59 on Mar 17, 2016. The Stock currently has the market capitalization of $621.04 Million, P/E (price to earnings ttm) of 44.8 and Weekly volatility of 3.62% and monthly volatility of 4.58% respectively.

Sucampo Pharmaceuticals, Inc. is currently showing 28.4% EPS growth this year. The Next Year EPS growth is 41%, Long term annual growth estimate of 11.75%, Annual EPS growth past 5 years of 41.99 percent. The Company currently has Insider ownership of 54.19 Percent and Institutional Ownership of 41.9 Percent. The Return on Assets stands at 2.9%, Return on Equity shows 11.7% and Return on Investment value is 10.1%.

Sucampo Pharmaceuticals, Inc. Gross Margin percentage stands at 63.6% while its Operating Margin for trailing twelve month is 15.1 percent and Profit margin (ttm) is 6.3 Percent. The stock is currently moving above its 20-Day Simple Moving Average of -7% with the 50-Day Simple Moving Average of -7 percent. Currently, the company has SMA200 (200-day simple moving average) of 8.55 Percent. The Stock has YTD (year to date) performance of -1.48 percent.

Many research firms have provided their ratings on Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) where Mizuho provided Buy rating on the stock on 22-Dec-16. Other firms include Northland Capital giving Outperform rating on 7-Sep-16.

The latest Insider trade was made on 30 Dec 2016 where Kiener Peter A Officer did a transaction type “Buy” in which 287 shares were traded at a price of $10.46. Another insider trade includes General Counsel Alder (Matthias) who also initiated a transaction in which 134 shares were traded on 30 Dec 2016 as “Buy”.

Company Profile:

Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders.